Author

Alroughani R

Amiri Hospital - Cited by 6,091 - Neurology - Multiple Sclerosis - Epidemiology

Biography

Raed Alroughani received a degree in medicine from Charles University. He finished his neurology residency from the University of British Columbia and obtained the neurology certification from the Royal College of Physicians & Surgeon (Canada). 
Title
Cited by
Year
Diagnosis and classification of optic neuritis
A Petzold, CL Fraser, M Abegg, R Alroughani, D Alshowaeir, R Alvarenga, ...The Lancet Neurology 21 (12), 1120-1134, 2022202
36
2022
Updated results of the COVID-19 in MS global data sharing initiative: anti-CD20 and other risk factors associated with COVID-19 severity
S Simpson-Yap, A Pirmani, T Kalincik, E De Brouwer, L Geys, T Parciak, ...Neurology-Neuroimmunology Neuroinflammation 9 (6), 2022202
14
2022
Disease reactivation after cessation of disease-modifying therapy in patients with relapsing-remitting multiple sclerosis
I Roos, C Malpas, E Leray, R Casey, D Horakova, EK Havrdova, ...Neurology 99 (17), e192-e1944, 2022202
6
2022
Risk factors of white matter hyperintensities in migraine patients
JY Al-Hashel, R Alroughani, K Gad, L Al-Sarraf, SF AhmedBMC neurology 22 (1), 1-9, 2022202
5
2022
Family planning considerations in people with multiple sclerosis
KM Krysko, R Dobson, R Alroughani, MP Amato, R Bove, AI Ciplea, ...The Lancet Neurology 22 (), 350-366, 2023202
4
2023
Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network
A Signori, J Lorscheider, S Vukusic, M Trojano, P Iaffaldano, J Hillert, ...Journal of Neurology, Neurosurgery & Psychiatry 9 (1), 23-30, 2023202
4
2023
Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β
S Simpson-Yap, A Pirmani, E De Brouwer, LM Peeters, L Geys, T Parciak, ...Multiple Sclerosis and Related Disorders 66, 10072, 2022202
4
2022
Comparative effectiveness in multiple sclerosis: A methodological comparison
I Roos, I Diouf, S Sharmin, D Horakova, EK Havrdova, F Patti, ...Multiple Sclerosis Journal 9 (3), 36-33, 030
2
2023
Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry
T Spelman, S Ozakbas, R Alroughani, M Terzi, S Hodgkinson, G Laureys, ...Multiple Sclerosis Journal 9 (), 1-35, 030
2
2023
Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis
C Zhu, Z Zhou, I Roos, D Merlo, T Kalincik, S Ozakbas, O Skibina, J Kuhle, ...Journal of Neurology, Neurosurgery & Psychiatry 93 (1), 1330-1337, 0
2
2022
A non-inferiority study of rituximab versus ocrelizumab in relapsing-remitting multiple sclerosis
I Roos, S Hughes, G MacDonnell, C Boz, R Alroughani, S Ozakbas, ...MULTIPLE SCLEROSIS JOURNAL 8 (3_ SUPPL), 951-953, 0
2
2022
Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis
I Roos, S Hughes, G McDonnell, CB Malpas, S Sharmin, C Boz, ...JAMA neurology, 2023202
1
2023
Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity
T Spelman, D Horakova, S Ozakbas, R Alroughani, M Onofrj, T Kalincik, ...Multiple Sclerosis and Related Disorders 70, 04477, 2023202
1
2023
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis
T Kalincik, S Sharmin, I Roos, MS Freedman, H Atkins, J Burman, ...JAMA Neurology, 2023202
1
2023

Referred From: https://scholar.google.com.my/citations?user=dwIorsYAAAAJ&hl=en

Cited by
Citations 6091
h-index 40
i10-index 111
Open Access Journals